#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
This article provides practical guidance on medicinal cannabis prescribing across multiple medical specialties, addressing a critical knowledge gap as cannabis-based medicines become increasingly integrated into evidence-based clinical practice. The resource covers safety considerations, patient selection criteria, and evidence-based prescribing pathways tailored to conditions commonly encountered in geriatric, oncologic, infectious disease, and other specialist settings. By consolidating safety data and practical protocols, the article aims to help clinicians navigate the regulatory landscape and minimize adverse effects while optimizing therapeutic benefit for appropriate patient populations. The work acknowledges that despite growing clinical interest, many physicians lack standardized guidance on how to safely integrate cannabinoid therapies into their practice. Clinicians should use this resource to establish baseline competency in patient screening, drug interaction assessment, and dose titration strategies, thereby improving patient safety and therapeutic outcomes when cannabinoid therapy is indicated. Physicians who familiarize themselves with these practical prescribing pathways will be better equipped to counsel patients on realistic expectations, contraindications, and monitoring requirements for medicinal cannabis use.
💊 While medicinal cannabis shows promise across diverse clinical specialties from geriatric to maternal medicine, the heterogeneity of cannabis products, variable cannabinoid compositions, and limited high-quality comparative trials create significant challenges for evidence-based prescribing. Healthcare providers should recognize that regulatory approval pathways and clinical evidence vary substantially by jurisdiction and indication, and that patient expectations may exceed current evidentiary support, particularly for off-label uses. Important confounders include individual variation in metabolism and cannabinoid sensitivity, potential drug interactions with common medications, and the difficulty of controlling for placebo effects in symptom-based conditions. Given these complexities, clinicians considering medicinal cannabis should employ a structured approach that documents clear therapeutic goals, establishes baseline symptom severity, uses standardized products with known cannabinoid content, and maintains close follow-up to assess efficacy and tolerability before expanding use. This systematic framework helps mitigate risks while allowing patients
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
